🧬 FCPS Paediatrics TOACS · Recurrent Neisseria meningitidis Septicemia
📖 Nelson's Chapter 164 · Inborn Errors of Immunity – Complement & Terminal Pathway Deficiencies
📚 paeds.online – Paeds Online
🩺 OBSERVED/INTERACTIVE STATION · CPSP FORMAT · 10 MINUTES · COMPLEMENT DEFICIENCY APPROACH
📋 Observed Station – “Recurrent meningococcal septicemia in a 7‑year‑old boy”
👦🏽 Clinical scenario (displayed / read to candidate):
A 7‑year‑old boy presents with his second episode of Neisseria meningitidis septicemia within 18 months. First episode (age 5 years) was serogroup C meningitis; current blood culture grows Neisseria meningitidis serogroup Y. He has no previous history of pneumonia, sinusitis, or other pyogenic infections. Between episodes he is healthy, growing well.
On examination: no dysmorphic features, no telangiectasia, no organomegaly. Immunizations: received meningococcal conjugate vaccine (MenACWY) at 12 months and booster at 4 years.
🎯 Task (examiner observed): Explain the most likely underlying primary immunodeficiency. Discuss the immunologic defect, targeted laboratory evaluation, interpretation of complement functional assays (CH50, AH50), and long‑term management including vaccination and antibiotic prophylaxis.
📸 Key concept from Nelson's Chapter 164: Recurrent invasive Neisseria infections are sentinel for terminal complement deficiencies (C5‑C9) or properdin deficiency (alternative pathway). Also consider asplenia, but this child has no Howell‑Jolly bodies or risk factors.
A 7‑year‑old boy presents with his second episode of Neisseria meningitidis septicemia within 18 months. First episode (age 5 years) was serogroup C meningitis; current blood culture grows Neisseria meningitidis serogroup Y. He has no previous history of pneumonia, sinusitis, or other pyogenic infections. Between episodes he is healthy, growing well.
On examination: no dysmorphic features, no telangiectasia, no organomegaly. Immunizations: received meningococcal conjugate vaccine (MenACWY) at 12 months and booster at 4 years.
🎯 Task (examiner observed): Explain the most likely underlying primary immunodeficiency. Discuss the immunologic defect, targeted laboratory evaluation, interpretation of complement functional assays (CH50, AH50), and long‑term management including vaccination and antibiotic prophylaxis.
📸 Key concept from Nelson's Chapter 164: Recurrent invasive Neisseria infections are sentinel for terminal complement deficiencies (C5‑C9) or properdin deficiency (alternative pathway). Also consider asplenia, but this child has no Howell‑Jolly bodies or risk factors.
🔬 Nelson's Table 164.4 – Recurrent invasive pneumococcal/Neisseria infections
Complement deficiencies (C5, C6, C7, C8, C9) & alternative pathway defects (properdin, factor D) predispose to Neisseria sepsis/meningitis. Terminal pathway deficiency impairs membrane attack complex (MAC) → ineffective killing of encapsulated organisms.
Complement deficiencies (C5, C6, C7, C8, C9) & alternative pathway defects (properdin, factor D) predispose to Neisseria sepsis/meningitis. Terminal pathway deficiency impairs membrane attack complex (MAC) → ineffective killing of encapsulated organisms.
Figure: Classical, Lectin, Alternative pathways converge at C3. Terminal components C5b–C9 form MAC. Deficiencies of C5–C9 → Neisseria susceptibility.
💡 Examiner probes: Why Neisseria specifically? → Terminal complement deficiency impairs serum bactericidal activity against encapsulated organisms; Neisseria is uniquely susceptible to MAC‑dependent killing. Also consider asplenia, but Howell‑Jolly bodies are absent; vaccination failure also possible but improbable with second episode.
🩸 Diagnostic approach – Inborn errors of immunity & complement testing
1 Initial screen
CBC with differential, peripheral smear (Howell‑Jolly bodies for asplenia), immunoglobulins (IgG, IgA, IgM), specific antibody titers (tetanus, pneumococcus).
CBC with differential, peripheral smear (Howell‑Jolly bodies for asplenia), immunoglobulins (IgG, IgA, IgM), specific antibody titers (tetanus, pneumococcus).
2 Complement functional assays
CH50 (classical pathway hemolytic activity) → low/absent in C1‑C9 deficiencies. AH50 (alternative pathway) → low in properdin, factor D, factor B, or terminal component defects.
CH50 (classical pathway hemolytic activity) → low/absent in C1‑C9 deficiencies. AH50 (alternative pathway) → low in properdin, factor D, factor B, or terminal component defects.
3 Interpretation pattern
Low CH50 + normal AH50 → classical pathway defect (C1, C2, C4). Low CH50 + low AH50 → terminal complement deficiency (C5‑C9) or factor B/D/properdin.
Low CH50 + normal AH50 → classical pathway defect (C1, C2, C4). Low CH50 + low AH50 → terminal complement deficiency (C5‑C9) or factor B/D/properdin.
4 Quantification of individual components
Immunochemical measurement of C5, C6, C7, C8, C9. Functional activity of specific component can be assessed via mixing studies.
Immunochemical measurement of C5, C6, C7, C8, C9. Functional activity of specific component can be assessed via mixing studies.
5 Properdin level & function
X‑linked properdin deficiency → low AH50, variable CH50; increased susceptibility to Neisseria, often fulminant sepsis.
X‑linked properdin deficiency → low AH50, variable CH50; increased susceptibility to Neisseria, often fulminant sepsis.
6 Genetic confirmation
Next‑generation sequencing for complement genes (C5, C6, C7, C8A, C8B, C9, PFD, CFB). Helps family screening and genetic counseling.
Next‑generation sequencing for complement genes (C5, C6, C7, C8A, C8B, C9, PFD, CFB). Helps family screening and genetic counseling.
⚠️ Critical points (Nelson's Ch 164):
• Terminal complement deficiency (C5‑C9) → risk of recurrent meningococcal disease but lower mortality than immunocompetent hosts.
• Properdin deficiency (X‑linked) → high case fatality rate, often presents with rapid septic shock.
• CH50 is the best screening test; a normal CH50 essentially excludes classical/terminal pathway deficiencies (except C9 deficiency may have mildly reduced CH50).
• All patients with unexplained recurrent Neisseria should have CH50 and AH50 performed.
• Terminal complement deficiency (C5‑C9) → risk of recurrent meningococcal disease but lower mortality than immunocompetent hosts.
• Properdin deficiency (X‑linked) → high case fatality rate, often presents with rapid septic shock.
• CH50 is the best screening test; a normal CH50 essentially excludes classical/terminal pathway deficiencies (except C9 deficiency may have mildly reduced CH50).
• All patients with unexplained recurrent Neisseria should have CH50 and AH50 performed.
📊 Example lab scenario (mock results):
CH50: <10 U/mL (normal 150–350) → severely reduced
AH50: <8% (normal 60–120%) → severely reduced
C3, C4 normal → points to late component or alternative pathway defect. C8 measured <5% → consistent with C8β deficiency. Genetic testing: homozygous variant in C8B.
CH50: <10 U/mL (normal 150–350) → severely reduced
AH50: <8% (normal 60–120%) → severely reduced
C3, C4 normal → points to late component or alternative pathway defect. C8 measured <5% → consistent with C8β deficiency. Genetic testing: homozygous variant in C8B.
🗨️ Examiner Q&A · Complement deficiencies · Inborn errors of immunity
❓ Q1 (Examiner): “Based on Nelson’s Chapter 164, which primary immunodeficiencies classically present with recurrent Neisseria infections?”
✅ Terminal complement component deficiencies (C5, C6, C7, C8, C9)
• Properdin deficiency (X‑linked, alternative pathway)
• Factor D deficiency (rare)
• Acquired asplenia/hyposplenism (but less specific)
CH50/AH50 screening is key.
• Properdin deficiency (X‑linked, alternative pathway)
• Factor D deficiency (rare)
• Acquired asplenia/hyposplenism (but less specific)
CH50/AH50 screening is key.
❓ Q2 (Examiner): “Why do patients with C5–C9 deficiency have a selective susceptibility to Neisseria but not to other encapsulated bacteria like pneumococcus?”
✅ Because serum bactericidal activity against Neisseria is largely dependent on the membrane attack complex (MAC). Pneumococci are effectively opsonized by C3b and cleared by phagocytes even in the absence of MAC. Terminal complement defects impair MAC formation → Neisseria survives in the bloodstream. Opsonophagocytosis remains intact for many other bacteria.
❓ Q3 (Examiner): “What is the role of CH50 and AH50 in diagnosing complement deficiency? How do you interpret an undetectable CH50?”
✅ CH50 measures the ability of patient serum to lyse antibody‑sensitized sheep erythrocytes (classical pathway). Undetectable CH50 indicates a defect in C1–C9. If also AH50 low → terminal or alternative pathway defect; if AH50 normal → classical pathway (C1, C2, C4). Complement consumption (SLE, infection) typically causes low but not absent CH50.
❓ Q4 (Examiner): “What is the risk of autoimmune disease in complement deficiencies?” (Based on Nelson’s Ch 164/173)
✅ Early classical pathway deficiencies (C1q, C1r/s, C4, C2) are strongly associated with systemic lupus erythematosus (SLE) due to impaired clearance of apoptotic debris. Terminal complement deficiencies (C5–C9) have a minimal risk of SLE, but neisserial infections dominate. Properdin deficiency has no strong lupus association.
❓ Q5 (Examiner): “How do you manage a child with confirmed C8 deficiency to prevent further episodes of meningococcal sepsis?”
✅ • Vaccination against Neisseria meningitidis (MenACWY and MenB vaccines) – even though antibody alone may be partially protective.
• Long‑term antibiotic prophylaxis – penicillin V or amoxicillin daily, or azithromycin (meningococcal coverage).
• Family screening: test siblings and parents (CH50/quantitative C8) → genetic counseling.
• Education about early signs of sepsis and emergency antibiotic self‑administration (IM ceftriaxone or oral ciprofloxacin when fever appears).
• In some patients, consider prophylactic complement blockade is NOT indicated; instead, boosters every 3‑5 years for meningococcal vaccines.
• Long‑term antibiotic prophylaxis – penicillin V or amoxicillin daily, or azithromycin (meningococcal coverage).
• Family screening: test siblings and parents (CH50/quantitative C8) → genetic counseling.
• Education about early signs of sepsis and emergency antibiotic self‑administration (IM ceftriaxone or oral ciprofloxacin when fever appears).
• In some patients, consider prophylactic complement blockade is NOT indicated; instead, boosters every 3‑5 years for meningococcal vaccines.
❓ Q6 (Examiner): “What is properdin deficiency? How does it differ from terminal complement deficiency?”
✅ Properdin is a positive regulator (stabilizer) of alternative pathway C3 convertase. X‑linked properdin deficiency causes markedly increased susceptibility to Neisseria, often with fulminant sepsis and high fatality compared to terminal defects. CH50 may be normal or mildly reduced; AH50 is very low. Treatment: vaccination, antibiotic prophylaxis, and family carrier detection.
❓ Q7 (Examiner): “Could this child have asplenia? How would you rule it out?”
✅ Asplenia (congenital or acquired) also predisposes to encapsulated organisms including Neisseria. Screening: peripheral smear for Howell‑Jolly bodies (absent spleen) and abdominal ultrasound to detect splenic tissue. Normal spleen size and absence of Howell‑Jolly bodies rule out asplenia. Also check for associated congenital syndromes (heterotaxy, cardiac defects).
❓ Q8 (Examiner): “What is the value of meningococcal vaccination in terminal complement deficiency? Does it completely eliminate risk?”
✅ Vaccination (MenACWY, MenB) reduces but does not eliminate risk because protective immunity relies on both antibody and complement. In MAC deficiency, bactericidal antibody alone cannot fully compensate. Nonetheless, it offers partial protection and primes memory B cells. Prophylactic antibiotics remain essential. Booster doses every 3‑5 years are recommended.
❓ Q9 (Examiner): “What additional lab tests should be ordered in the evaluation of recurrent invasive Neisseria?”
✅ • CH50, AH50, then individual complement component levels (C5–C9, properdin).
• Quantitative immunoglobulins and specific antibody responses (pneumococcal, tetanus) to exclude antibody deficiency.
• Flow cytometry for CD55/CD59 (PNH clone rarely, but not primarily).
• Genetic panel for inborn errors of immunity (complement genes, IRAK4/MyD88 if also invasive pneumococcal with poor fever).
• Functional assay of MAC formation (optional research).
• Quantitative immunoglobulins and specific antibody responses (pneumococcal, tetanus) to exclude antibody deficiency.
• Flow cytometry for CD55/CD59 (PNH clone rarely, but not primarily).
• Genetic panel for inborn errors of immunity (complement genes, IRAK4/MyD88 if also invasive pneumococcal with poor fever).
• Functional assay of MAC formation (optional research).
❓ Q10 (Examiner): “What is the ‘sentinel infection’ concept in PID according to Nelson’s 164? List three sentinel infections that should trigger immune workup.”
✅ Sentinel infections are specific pathogens that strongly suggest a particular immune defect:
• Neisseria meningitidis → terminal complement or properdin deficiency
• Pneumocystis jirovecii → T‑cell deficiency (SCID, CD40L, MHC‑II)
• Burkholderia cepacia / Serratia marcescens → chronic granulomatous disease (CGD)
• Atypical mycobacteria or BCGosis → IL‑12/IFN‑γ pathway defects (MSMD)
• Neisseria meningitidis → terminal complement or properdin deficiency
• Pneumocystis jirovecii → T‑cell deficiency (SCID, CD40L, MHC‑II)
• Burkholderia cepacia / Serratia marcescens → chronic granulomatous disease (CGD)
• Atypical mycobacteria or BCGosis → IL‑12/IFN‑γ pathway defects (MSMD)
📘 Nelson’s Chapter 164 & 173 – Management of complement deficiencies / PID
🔬 Diagnosis pathway (Fig 164.1)
Recurrent Neisseria → suspect complement defect → CH50/AH50 → if low, measure terminal components (C5‑C9). Always rule out asplenia.
Recurrent Neisseria → suspect complement defect → CH50/AH50 → if low, measure terminal components (C5‑C9). Always rule out asplenia.
💊 Antimicrobial prophylaxis
Penicillin V or amoxicillin daily; alternative: azithromycin (meningococcal coverage). Early antibiotic treatment at fever onset (intramuscular ceftriaxone or oral ciprofloxacin).
Penicillin V or amoxicillin daily; alternative: azithromycin (meningococcal coverage). Early antibiotic treatment at fever onset (intramuscular ceftriaxone or oral ciprofloxacin).
💉 Vaccination schedule
MenACWY (conjugated) + MenB (recombinant) vaccines. Boosters every 3‑5 years. Hib, pneumococcal vaccines also recommended. Avoid live vaccines (not contraindicated unless combined SCID).
MenACWY (conjugated) + MenB (recombinant) vaccines. Boosters every 3‑5 years. Hib, pneumococcal vaccines also recommended. Avoid live vaccines (not contraindicated unless combined SCID).
👨👩👦 Family screening
First‑degree relatives: CH50 and specific component assays. Autosomal recessive inheritance for most terminal deficiencies. Genetic counseling is essential.
First‑degree relatives: CH50 and specific component assays. Autosomal recessive inheritance for most terminal deficiencies. Genetic counseling is essential.
⚠️ Emergency plan
Provide “sepsis emergency card” and home antibiotic kit. Early presentation to ER for any fever. Consider medical alert bracelet: “Terminal complement deficiency – risk of fulminant meningococcemia”.
Provide “sepsis emergency card” and home antibiotic kit. Early presentation to ER for any fever. Consider medical alert bracelet: “Terminal complement deficiency – risk of fulminant meningococcemia”.
🧬 Alternative pathway defects
Properdin deficiency (X‑linked) – screen males in family. Factor D deficiency (very rare) similar Neisseria susceptibility. All need prophylaxis + education.
Properdin deficiency (X‑linked) – screen males in family. Factor D deficiency (very rare) similar Neisseria susceptibility. All need prophylaxis + education.
📖 Nelson’s Textbook quotation (Chapter 164): “Terminal complement (C5‑C9) and alternative complement defects (properdin or factor D deficiency) have increased susceptibility to recurrent invasive Neisseria species (recurrent meningococcal and disseminated gonococcal infections). CH50 screening is the initial test of choice; undetectable CH50 with low AH50 indicates a terminal pathway defect.”
⭐ TOACS TAKE‑HOME POINTS (for candidates):
1. Recurrent meningococcal disease → always evaluate for terminal complement deficiency or properdin deficiency.
2. CH50 + AH50 are first‑line functional assays. Absent CH50 + low AH50 → C5‑C9 defect.
3. Vaccination (MenACWY, MenB) and daily penicillin/azithromycin reduce but do not eliminate risk.
4. Provide family with emergency antibiotics and fever action plan.
5. Screen family members; treat identified asymptomatic deficiencies similarly.
6. Differentiate from asplenia (Howell‑Jolly bodies, ultrasound).
7. Autoimmune disease (SLE) is not a feature of terminal complement defects but common in C1/C4 deficiency.
1. Recurrent meningococcal disease → always evaluate for terminal complement deficiency or properdin deficiency.
2. CH50 + AH50 are first‑line functional assays. Absent CH50 + low AH50 → C5‑C9 defect.
3. Vaccination (MenACWY, MenB) and daily penicillin/azithromycin reduce but do not eliminate risk.
4. Provide family with emergency antibiotics and fever action plan.
5. Screen family members; treat identified asymptomatic deficiencies similarly.
6. Differentiate from asplenia (Howell‑Jolly bodies, ultrasound).
7. Autoimmune disease (SLE) is not a feature of terminal complement defects but common in C1/C4 deficiency.
🔗 Online resources for candidates & families:
• Paeds Online – FCPS revision & TOACS bank
• Immune Deficiency Foundation – Complement deficiencies
• CDC Meningococcal disease & complement deficiency
• Paeds Online – FCPS revision & TOACS bank
• Immune Deficiency Foundation – Complement deficiencies
• CDC Meningococcal disease & complement deficiency